Bicara Therapeutics Appoints Chris Sarchi as Chief Commercial Officer Ahead of Potential Accelerated Drug Approval
Bicara Therapeutics has announced the appointment of Chris Sarchi as its new chief commercial officer, a strategic move as the company prepares for a potential accelerated approval of its cancer drug next year. Sarchi brings a wealth of experience from his previous roles at Replimune and Sanofi, where he honed his skills in commercial strategy…









